Cellectar Biosciences EBITDA 2010-2025 | CLRB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cellectar Biosciences ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cellectar Biosciences ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$216.5B
Boston Scientific (BSX)	$153.5B
Stryker (SYK)	$147.8B
EssilorLuxottica (ESLOY)	$131.6B
Medtronic (MDT)	$115B
Lonza Group Ag (LZAGY)	$49.2B
Haleon (HLN)	$42.8B
ResMed (RMD)	$38.3B
GE HealthCare Technologies (GEHC)	$34B
Agilent Technologies (A)	$31.8B
Terumo (TRUMY)	$24.2B
Koninklijke Philips (PHG)	$23.6B
Insulet (PODD)	$19.8B
Zimmer Biomet Holdings (ZBH)	$18.3B
Baxter (BAX)	$14B
Smith & Nephew SNATS (SNN)	$13.3B
Sunny Optical Technology (SNPTF)	$10.4B
Demant (WILYY)	$8.6B
Bio-Rad Laboratories (BIO)	$6.6B
Lantheus Holdings (LNTH)	$5B
Prestige Consumer Healthcare (PBH)	$3.7B
Perrigo (PRGO)	$3.7B
Haemonetics (HAE)	$3.5B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Envista Holdings (NVST)	$3.3B
ICU Medical (ICUI)	$3B
LeMaitre Vascular (LMAT)	$1.8B
QuidelOrtho (QDEL)	$1.7B
AtriCure (ATRC)	$1.4B
Acuren (TIC)	$1.4B